The Effect of Single High-Dose Preoperative Intravenous Tranexamic Acid Administration to Reduce Blood Loss in Patients with Primary Total Knee Replacement

Mehmet Ali Talmacı, Mehmet Akif Görgel, Sema Ertan Birsel, Mehmet Mesut Sönmez, Hacı Mustafa Özdemir

Department of Orthopaedics, Health Sciences University Sisli Etfal Training and Research Hospital, Istanbul, Turkey
Department of Orthopaedics, Istanbul Private Medicine Hospital, Istanbul, Turkey

Abstract

Objectives: This study aimed to analyze the efficacy of single-dose tranexamic acid (TA) 20 mg/kg preoperatively to reduce blood loss in patients undergoing total knee replacement (TKR).

Methods: A total of 387 patients (82 males, 305 females) undergoing TKR between January 2014 and December 2018 were included in the study. The T + group was administrated intravenous (iv) TA 20 mg/kg 20 min before the skin incision. We determined perioperative blood loss, the amount of drainage postoperative 24 h, the amount of drainage after postoperative 24–48 h, total volume of drains, total volume of blood loss, postoperative hemoglobin and hematocrit levels, and amount of total blood transfusion.

Results: In terms of demographic data, no statistically significant difference was observed between the groups. Perioperative blood loss and total volume of blood loss was found statistically higher in T − group compared to T + group. Postoperatively, the mean hemoglobin and hematocrit levels of T − group were statistically significantly lower than T + group.

Conclusion: A single 20 mg/kg iv TA administration before TKR reduces bleeding during surgery and within 24 h postoperatively.

Keywords: Blood loss; deep vein thrombosis; knee replacement; tranexamic acid.

In clinical practice, different protective measures such as autologous blood transfusion have been used to reduce postoperative blood transfusion rates. Other methods for prevention of perioperative blood loss include preoperative administration of erythropoietin, preoperative administration of iron supplements, normovolemic hemodilution, controlled hypotension, tourniquet use, and application of antifibrinolytic agents.

Tranexamic acid (TA) is a lysine analog that blocks plas-
minogen-binding sites by preventing complex formation between plasminogen, fibrin, and tissue plasminogen activator.\cite{13-15} TA is an inexpensive and easily accessible synthetic product.\cite{16-19} TA has been shown as an effective and safe product to reduce blood transfusion and blood loss in TKR without increasing thromboembolic complications in TKR.\cite{20,21} Several previous clinical studies and meta-analysis reports have demonstrated the efficacy of TA administered intraoperatively in the prevention of blood loss in TKR.\cite{22-26}

Methods

This study was designed as a retrospective clinical study and was approved by the University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital Clinical Research Ethics Committee. A total of 387 patients (82 men, 305 women) who underwent primary cemented TKR between January 2014 and December 2018 for knee osteoarthritis were included in this study. The mean age was 67.2 years (range 60–84 years). Exclusion criteria were having chronic renal, liver, rheumatic, or hematological diseases; history of thromboembolism; cerebrovascular diseases; simultaneous bilateral knee replacement; having undergone revision surgery; prolonged use of anticoagulant medication (≥3 months; The American College of Chest Physicians (ACCP) guidelines 2012); thrombocyte level below 150,000; and INR level above 1.4.

According to whether TA was given or not, patients were divided into two groups: T – group and T + group. The T + group was administrated intravenous (iv) TA 20 mg/kg 20 min before the skin incision. TA was not administered to the T – group patients. All patients underwent spinal or combined spinal epidural anesthesia. TKR was performed with standard medial parapatellar incision. Intramedullary guides were used for femoral cuts, and extramedullary guides were used for tibial cuts. The tourniquet was used only during cementing. In all TKR operations, the same type of knee implant that protects the posterior cruciate ligaments was used. The drainage was recorded at the 24th and 48th hour. Standard thromboembolism prophylaxis was applied in accordance with ACCP guidelines 2012, independent of age and weight. One dose of 0.4 ml (4000 IU) of enoxaparin was subcutaneously (sc) given 12 h prior to surgery. All patients received 0.4 ml (4000 IU) per day of enoxaparin sc for 14 days after discharge.

Blood counts were evaluated at the 6th hours postoperatively. Blood transfusion indication was given when the hemoglobin level was below 8 or 9 g/dL. When the hemoglobin values decreased under 9 g/dL, the patients received one unit of allogeneic erythrocytes suspension. When the hemoglobin values decreased under 8 g/dL, the patients received two units of allogeneic erythrocytes suspension. Fresh frozen plasma was not used. Intraoperative blood loss amount was calculated from aspiration and irrigation fluids.

The basic characteristics of groups were based on the mean age, male to female ratio, body mass index (BMI), and mean preoperative hemoglobin and hematocrit values. Perioperative blood loss, amount of blood drainage in postoperative 24 h and 48 h, total volume of drains, total volume of blood loss, and amount of blood transfusion were reviewed and compared between the two groups.

Statistical Analysis

The SPSS 15.0 for Windows 7 program was used for statistical analysis. Descriptive statistics were described as number and percentage for categorical variables, and mean and standard deviation for numerical variables. When numerical variables provided normal distribution condition, independent two-group comparisons were made by Student’s t test; and when normal distribution condition was not provided, Mann–Whitney U test was used. The ratios in groups were compared with the chi-square test. Statistical significance level of alpha was accepted as p<0.05.

Results

No statistically significant difference was observed between groups with respect to the mean age, male to female ratio, BMI, American Society of Anesthesiologists grade ratios, and mean preoperative hemoglobin and hematocrit values (Table 1). There was no significant difference in pre-

<table>
<thead>
<tr>
<th>Table 1. Preoperative demographics</th>
<th>T - group</th>
<th>T + group</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (year) (mean±SD)</td>
<td>67.4±3.9</td>
<td>67.0±4.5</td>
<td>0.079</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td>0.601</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>218 (78.1)</td>
<td>87 (80.6)</td>
<td></td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>61 (21.9)</td>
<td>21 (19.4)</td>
<td></td>
</tr>
<tr>
<td>Body mass index (kg/m²) (mean±SD)</td>
<td>31.5±2.9</td>
<td>31.4±2.6</td>
<td>0.767</td>
</tr>
<tr>
<td>American Society of Anesthesiologists grade</td>
<td></td>
<td></td>
<td>0.739</td>
</tr>
<tr>
<td>Grade I, n (%)</td>
<td>27 (9.7)</td>
<td>10 (9.3)</td>
<td></td>
</tr>
<tr>
<td>Grade II, n (%)</td>
<td>45 (16.1)</td>
<td>21 (19.4)</td>
<td></td>
</tr>
<tr>
<td>Grade III, n (%)</td>
<td>207 (74.2)</td>
<td>77 (71.3)</td>
<td></td>
</tr>
<tr>
<td>Preoperative hemoglobin (g/dL) (mean±SD)</td>
<td>12.1±1.2</td>
<td>12.2±1.2</td>
<td>0.537</td>
</tr>
<tr>
<td>Preoperative hematocrit (mean±SD)</td>
<td>36.2±3.6</td>
<td>36.5±3.6</td>
<td>0.333</td>
</tr>
</tbody>
</table>

The values are expressed as mean±SD or numbers of patients (n (%)). There are no significant differences between groups. P<0.05 was considered to indicate statistical significance.
operative comorbidity rates (Table 2). Statistical analysis showed that perioperative blood loss, drainage blood loss 0–24 h, total volume of drains, and total volume of blood loss were statistically higher than T + group in T − group. But no statistically significant difference was observed between the two groups in the aspect of drainage blood loss between 24 h and 48 h (Table 3) (Fig. 1). When the mean hemoglobin and hematocrit values measured at the 6th hour postoperatively were examined, it was found that the T − group results was statistically lower than the T + group’s (Table 4). Allogeneic blood transfusion amount in the T − group was significantly higher than in the T + group (Fig. 2). But no statistically significant difference was observed between the two groups in terms of postoperative hospital stay (days) (Table 4).

### Discussion

Primer cemented TKR can result in significant amounts of blood loss. The mean total blood loss according to various studies ranged from 400 to 2000 ml.[27] Surgical trauma increases perioperative blood loss through fibrinolysis activation.[28] TA is the inhibitor of fibrinolysis that reduces postoperative blood loss. Hippala et al.[29] first published the use of TA as an antifibrinolytic agent to reduce blood loss after TKR. TA is widely used in various surgical applications, but recently it has begun to be used in TKR. TA is administered in the form of different methods. Following iv application, TA is rapidly dispersed into synovial fluid.[12] Many publications show that TA administration causes significant reduction in the blood loss.[29–32] Our study showed that the average amount of blood loss in the TA-receiving group was 656.7±57.4 ml and the blood loss in the non-TA group's (Table 4). Allogeneic blood transfusion amount in the T − group was significantly higher than in the T + group (Fig. 2). But no statistically significant difference was observed between the two groups in terms of postoperative hospital stay (days) (Table 4).

### Table 2. Preoperative comorbidities

<table>
<thead>
<tr>
<th></th>
<th>T − group n (%)</th>
<th>T + group n (%)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthma</td>
<td>4 (1.4)</td>
<td>2 (1.9)</td>
<td>0.673</td>
</tr>
<tr>
<td>CAD</td>
<td>9 (3.2)</td>
<td>3 (3.1)</td>
<td>0.714</td>
</tr>
<tr>
<td>DM</td>
<td>89 (31.9)</td>
<td>29 (26.9)</td>
<td>0.333</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>17 (6.1)</td>
<td>8 (7.4)</td>
<td>0.637</td>
</tr>
<tr>
<td>HT</td>
<td>123 (44.1)</td>
<td>53 (49.1)</td>
<td>0.377</td>
</tr>
<tr>
<td>Thyroid</td>
<td>14 (5.0)</td>
<td>4 (3.7)</td>
<td>0.582</td>
</tr>
</tbody>
</table>

The values are expressed as numbers of patients (n (%)). There are no significant differences between groups. CAD: Coronary artery diseases. DM: Diabetes mellitus. HT: Hypertension. P<0.05 was considered statistically significant.

### Table 3. Blood loss data

<table>
<thead>
<tr>
<th></th>
<th>T − group (mean±SD)</th>
<th>T + group (mean±SD)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perioperative blood loss (ml)</td>
<td>493.5±42.4</td>
<td>257.9±35.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Drainage blood loss 0–24 h (ml)</td>
<td>637.6±57.7</td>
<td>306.5±35.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Drainage blood loss 24–48 h (ml)</td>
<td>93.3±17.7</td>
<td>92.4±16.2</td>
<td>0.932</td>
</tr>
<tr>
<td>Total volume of drains (ml)</td>
<td>730.9±60.5</td>
<td>398.8±41.9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Total volume of blood loss (ml)</td>
<td>1224.5±71.9</td>
<td>656.7±57.4</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

The values are expressed as mean±SD. P<0.05 was considered statistically significant.

### Table 4. Comparison outcomes between the groups

<table>
<thead>
<tr>
<th></th>
<th>T − group (mean±SD)</th>
<th>T + group (mean±SD)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Postoperative hemoglobin 6 h (g/dL)</td>
<td>9.0±1.2</td>
<td>10.1±1.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Postoperative hematocrit 6 h</td>
<td>26.9±3.7</td>
<td>30.4±3.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Postoperative hospital stay (days)</td>
<td>4.3±0.6</td>
<td>4.1±0.4</td>
<td>0.337</td>
</tr>
<tr>
<td>Total (perioperative and postoperative 48 h) transfusion (unit)</td>
<td>1.7±0.5</td>
<td>1.0±0.0</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

The values are expressed as mean±SD. P<0.05 was considered statistically significant.

---

Figure 1. Perioperative and postoperative 48 hours blood loss(ml): Perioperative blood loss and drainage blood loss 0–24 hours were statistically higher than TXA + group in TXA - group. But there was no statistically significant difference between the two groups in the results of drainage blood loss between 24–28 hours.

Figure 2. Total allogeneic blood transfusion units: Allogeneic blood transfusion level in the TXA - group was significantly higher than in the TXA + group.
The most important limitation of our study is that four different surgeons performed the surgeries. Although all surgeons have extensive experience in the field of knee replacement surgery, individual differences could affect perioperative blood loss. Another limitation is the retrospective nature of the study. On the other hand, it was the advantage of studying the inclusion of 387 patients and the use of the same type of knee implants.

Conclusion

In conclusion, the use of single and high doses of TA in patients with TKRs significantly reduces blood loss during surgery and in the first 24 h postoperatively. There is no significant reduction in blood loss after 24 h. Preoperative iv TA administration significantly reduced the rate of allo-genic erythrocyte suspensions. The above results showed that administration of intravenous high-dose TA prior to TKR did not increase complications, contributed significantly to the vital stability of the patient by reducing blood loss, and thus should be routinely performed in appropriate patients.

Disclosures

Ethics Committee Approval: This study was designed as a retrospective clinical study and was been approved by University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital Clinical Research Ethics Committee.

Peer-review: Externally peer-reviewed.

Conflict of Interest: None declared.


References


2. Triulzi DJ, Vaneck K, Ryan DH, Blumberg N. A clinical and immunologic study of blood transfusion and postoperative bacterial in-
fection in spinal surgery. Transfusion 1992;32:517–24. [CrossRef]


15. Guerreiro JPF, Badaro BS, Balbino JRM, Danieli MV, Queiroz AO, Cataneo DC. Application of Tranexamic Acid in Total Knee Arthroplasty - Prospective Randomized Trial. Open Orthop J 2017;11:1049–1057. [CrossRef]


30. Talmaç et al., Tranexamic Acid Administration in Patients with Primary Total Knee Replacement / doi: 10.14744/SEMB.2018.73604


